DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Roland M. Huber 1 , Jared M. Lucas 1 , Luis A. Gomez-Sarosi 1 , Ilsa Coleman 1 , Song Zhao 1 , Roger Coleman 1 and Peter S. Nelson 1,2 1 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 2 Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Correspondence: Peter S. Nelson, email: // Keywords : microenvironment, paracrine, resistance, prostate cancer, treatment Received : October 21, 2014 Accepted : December 09, 2014 Published : December 10, 2014 Abstract Though metastatic cancers often initially respond to genotoxic therapeutics, acquired resistance is common. In addition to cytotoxic effects on tumor cells, DNA damaging agents such as ionizing radiation and chemotherapy induce injury in benign cells of the tumor microenvironment resulting in the production of paracrine-acting factors capable of promoting tumor resistance phenotypes. In studies designed to characterize the responses of prostate and bone stromal cells to genotoxic stress, we found that transcripts encoding glial cell line-derived neurotrophic factor (GDNF) increased several fold following exposures to cytotoxic agents including radiation, the topoisomerase inhibitor mitoxantrone and the microtubule poison docetaxel. Fibroblast GDNF exerted paracrine effects toward prostate cancer cells resulting in enhanced tumor cell proliferation and invasion, and these effects were concordant with the expression of known GDNF receptors GFRA1 and RET. Exposure to GDNF also induced tumor cell resistance to mitoxantrone and docetaxel chemotherapy. Together, these findings support an important role for tumor microenvironment damage responses in modulating treatment resistance and identify the GDNF signaling pathway as a potential target for improving responses to conventional genotoxic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towards a knowledge-based Human Protein Atlas
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1210-1248 · Cited by 2,440
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895 · cited 1×
“DNA damaging regimens are used focally in the case of radiation to the primary site or discrete metastatic foci, regionally in the case of bone-directed radioisotopes such as RAD-223, and systemically when using genotoxic chemotherapeutics for the treatment of CRPC which often metastasizes to bone [19].”
BackgroundA network-based analysis of systemic inflammation in humans
Program, I. A. H. R. T. I. L. S. C. R., Calvano, S. E., Xiao, W., Richards, D. R., Felciano, R. M., Baker, H. V., Cho, R. J., Chen, R. O., Brownstein, B. H., Cobb, J. P., et al. (2005) · Nature · doi:10.1038/nature03985 · Cited by 1,429
Autonomic nerve development contributes to prostate cancer progression
Magnon, C., Hall, S. J., Lin, J., Xue, X., Gerber, L., Freedland, S. J., & Frenette, P. S. (2013) · Science · doi:10.1126/science.1236361 · Cited by 1,287
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793 · cited 3×
“We previously profiled the gene expression alterations in prostate fibroblasts following DNA damage and identified a spectrum of highly induced transcripts of which a subset encoded secreted proteins including GDNF [6].”
BackgroundInfluentialSelf-citationDNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428
Cited by
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a
He, R., Liu, P., Xie, X., Zhou, Y., Liao, Q., Xiong, W., Li, X., Li, G., Zeng, Z., & Tang, H. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0614-1 · Cited by 347
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Tumor-induced generation of splenic erythroblast-like Ter-cells promotes tumor progression.
Han, Y., Liu, Q., Hou, J., Gu, Y., Zhang, Y., Chen, Z., Fan, J., Zhou, W., Qiu, S., Zhang, Y., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.061 · Cited by 150
Neurotrophic Factors and Their Potential Applications in Tissue Regeneration
Xiao, N., & Le, Q.-T. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0376-4 · Cited by 93
“GDNF family members also increase resistance to the chemotherapy in the prostate (Huber et al. 2015) and breast cancer (Ding et al.”
Metadata
- Authors
- Huber, R. M., Lucas, J. M., Gomez-Sarosi, L. A., Coleman, I., Zhao, S., Coleman, R., & Nelson, P. S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-12-10
- Volume
- 6
- Issue
- 4
- Pages
- 2134-2147
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1882882294
- Cited by
- 56
- References
- 6
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.